Arthroplasty in haemophilia: Double‐edged sword in low/middle‐income countries
暂无分享,去创建一个
P. Kouides | A. Forsyth | L. Solimeno | S. Marahatta | S. Tuladhar | Bishesh Sharma Poudyal | V. Prajapati | D. Rc | Sachita Rayamajhi | Bishal Poudel | Malika Bajrachrya | Samir Neupane | A. Rayamajhi
[1] C. Königs,et al. Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A. , 2019, Blood.
[2] E. Rodríguez‐Merchán. Risks and patient outcomes of surgical intervention for hemophilic arthropathy , 2019, Expert review of hematology.
[3] J. Mahlangu,et al. HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries , 2019, TH Open.
[4] B. Gyawali,et al. Use of donated clotting factors for surgeries on haemophilic patients in a resource‐constrained country: a kind donor, good outcome, change of practice and future directions , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] V. Ramanan,et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.
[6] M. Belhani,et al. Orthopaedic Status and Surgical Needs of Patients with Haemophilia in Algeria , 2013 .
[7] E. Berntorp,et al. Differences between developed and developing countries in paediatric care in haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] Y. Ayob. Management of hemophilia in resource-limited countries , 2008 .
[9] J. G. van der Bom,et al. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. , 2007, Blood.